DOCSLIB.ORG

Number 7 July 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Number 7 July 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology Volume 1 - Number 1 May - September 1997 Volume 23 - Number 7 July 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematology is a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It is made for and by: clinicians and researchers in cytogenetics, molecular biology, oncology, haematology, and pathology. One main scope of the Atlas is to conjugate the scientific information provided by cytogenetics/molecular genetics to the clinical setting (diagnostics, prognostics and therapeutic design), another is to provide an encyclopedic knowledge in cancer genetics. The Atlas deals with cancer research and genomics. It is at the crossroads of research, virtual medical university (university and post-university e-learning), and telemedicine. It contributes to "meta-medicine", this mediation, using information technology, between the increasing amount of knowledge and the individual, having to use the information. Towards a personalized medicine of cancer. It presents structured review articles ("cards") on: 1- Genes, 2- Leukemias, 3- Solid tumors, 4- Cancer-prone diseases, and also 5- "Deep insights": more traditional review articles on the above subjects and on surrounding topics. It also present 6- Case reports in hematology and 7- Educational items in the various related topics for students in Medicine and in Sciences. The Atlas of Genetics and Cytogenetics in Oncology and Haematology does not publish research articles. See also: http://documents.irevues.inist.fr/bitstream/handle/2042/56067/Scope.pdf Editorial correspondance Jean-Loup Huret, MD, PhD, [email protected] Editor, Editorial Board and Publisher See:http://documents.irevues.inist.fr/bitstream/handle/2042/48485/Editor-editorial-board-and-publisher.pdf The Atlas of Genetics and Cytogenetics in Oncology and Haematology is published 12 times a year by ARMGHM, a non profit organisation, and by the INstitute for Scientific and Technical Information of the French National Center for Scientific Research (INIST-CNRS) since 2008. The Atlas is hosted by INIST-CNRS (http://www.inist.fr) Staff: Vanessa Le Berre Philippe Dessen is the Database Directorof the on-line version (Gustave Roussy Institute – Villejuif – France). Publisher Contact: INIST-CNRS Mailing Address: Catherine Morel, 2,Allée du Parc de Brabois, CS 10130, 54519 Vandoeuvre-lès-Nancy France. Email Address:[email protected] Articles of the ATLAS are free in PDF format, and metadata are available on the web in Dublin Core XML format and freely harvestable.A Digital object identifier (DOI®), recorded at the International Agency CrossRefhttp://www.crossref.org/ is assigned to each article. http://AtlasGeneticsOncology.org © ATLAS - ISSN 1768-3262 The PDF version of the Atlas of Genetics and Cytogenetics in Oncology and Haematology is a reissue of the original articles published in collaboration with the Institute for Scientific and Technical Information (INstitut de l’Information Scientifique et Technique - INIST) of the French National Center for Scientific Research (CNRS) on its electronic publishing platform I-Revues. Online and PDF versions of the Atlas of Genetics and Cytogenetics in Oncology and Haematology are hosted by INIST-CNRS. Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Editor-in-Chief Jean-Loup Huret (Poitiers, France) Lymphomas Section Editor Antonino Carbone (Aviano, Italy) Myeloid Malignancies Section Editor Robert S. Ohgami (Stanford, California) Bone Tumors Section Editor Judith Bovee (Leiden, Netherlands) Head and Neck Tumors Section Editor Cécile Badoual (Paris, France) Urinary Tumors Section Editor Paola Dal Cin (Boston, Massachusetts) Pediatric Tumors Section Editor Frederic G. Barr (Bethesda, Maryland) Cancer Prone Diseases Section Editor Gaia Roversi (Milano, Italy) Cell Cycle Section Editor João Agostinho Machado-Neto (São Paulo, Brazil) DNA Repair Section Editor Godefridus Peters (Amsterdam, Netherlands) Hormones and Growth factors Section Editor Gajanan V. Sherbet (Newcastle upon Tyne, UK) Mitosis Section Editor Patrizia Lavia (Rome, Italy) WNT pathway Section Editor Alessandro Beghini (Milano, Italy) B-cell activation Section Editors Anette Gjörloff Wingren and Barnabas Nyesiga (Malmö, Sweden) Oxidative stress Section Editor Thierry Soussi (Stockholm, Sweden/Paris, France) Board Members Sreeparna Banerjee Department of Biological Sciences, Middle East Technical University, Ankara, Turkey; [email protected] Alessandro Department of Health Sciences, University of Milan, Italy; [email protected] Beghini Judith Bovée 2300 RC Leiden, The Netherlands; [email protected] Dipartimento di ScienzeMediche, Sezione di Ematologia e Reumatologia Via Aldo Moro 8, 44124 - Ferrara, Italy; Antonio Cuneo [email protected] Paola Dal Cin Department of Pathology, Brigham, Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; [email protected] IRBA, Departement Effets Biologiques des Rayonnements, Laboratoire de Dosimetrie Biologique des Irradiations, Dewoitine C212, François Desangles 91223 Bretigny-sur-Orge, France; [email protected] Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, Roosevelt Dr. Oxford, OX37BN, UK Enric Domingo [email protected] Ayse Elif Erson- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey; [email protected] Bensan Ad Geurts van Department of Human Genetics, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6500 HB Kessel Nijmegen, The Netherlands; [email protected] Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University Vienna, Children's Cancer Oskar A. Haas Research Institute Vienna, Vienna, Austria. [email protected] Anne Hagemeijer Center for Human Genetics, University Hospital Leuven and KU Leuven, Leuven, Belgium; [email protected] Department of Pathology, The Ohio State University, 129 Hamilton Hall, 1645 Neil Ave, Columbus, OH 43210, USA; Nyla Heerema [email protected] Sakari Knuutila Hartmann Institute and HUSLab, University of Helsinki, Department of Pathology, Helsinki, Finland; [email protected] Lidia Larizza Lab Centro di Ricerche e TecnologieBiomedicheIRCCS-IstitutoAuxologico Italiano Milano, Italy; l.larizza@auxologico Department of Human, Animal Cell Lines, Leibniz-Institute DSMZ-German Collection of Microorganisms, Cell Cultures, Braunschweig, Roderick Mc Leod Germany; [email protected] Cristina Mecucci Hematology University of Perugia, University Hospital S.Mariadella Misericordia, Perugia, Italy; [email protected] Department of Clinical Genetics, University and Regional Laboratories, Lund University, SE-221 85 Lund, Sweden; Fredrik Mertens [email protected] Konstantin Miller Institute of Human Genetics, Hannover Medical School, 30623 Hannover, Germany; [email protected] Department of Clinical Genetics, University and Regional Laboratories, Lund University, SE-221 85 Lund, Sweden; Felix Mitelman [email protected] Hossain Mossafa Laboratoire CERBA, 95066 Cergy-Pontoise cedex 9, France; [email protected] Department of Human, Animal Cell Lines, Leibniz-Institute DSMZ-German Collection of Microorganisms, Cell Cultures, Braunschweig, Stefan Nagel Germany; [email protected] Florence Pedeutour Laboratory of Solid Tumors Genetics, Nice University Hospital, CNRSUMR 7284/INSERMU1081, France; [email protected] Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 250, Memphis, Tennessee 38105- Susana Raimondi 3678, USA; [email protected] Clelia Tiziana Department of Biology, University of Bari, Bari, Italy; [email protected] Storlazzi Sabine Strehl CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschunge.V., Vienna, Austria; [email protected] Nancy Uhrhammer Laboratoire Diagnostic Génétique et Moléculaire, Centre Jean Perrin, Clermont-Ferrand, France; [email protected] Dan L. Van Dyke Mayo Clinic Cytogenetics Laboratory, 200 First St SW, Rochester MN 55905, USA; [email protected] Universita di Cagliari, Dipartimento di ScienzeBiomediche(DiSB), CittadellaUniversitaria, 09042 Monserrato (CA) - Italy; Roberta Vanni [email protected] Atlas Genet Cytogenet Oncol Haematol. 2019; 23(7) Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Volume 23, Number 7, July 2019 Table of contents Gene Section BIRC5 (baculoviral IAP repeat containing 5) 168 Paola Cristina Branco, Paula Christine Jimenez, João Agostinho Machado-Neto, Letícia Veras Costa-Lotufo SLC45A2 (solute carrier family 45 member 2) 187 Mainak Sengupta, Tithi Dutta, Kunal Ray Leukaemia Section Burkitt's lymphoma (BL) 190 Luis Miguel Juárez Salcedo, Ana Corazón Monzón, Samir Dalia t(X;14)(p22;q32) or t(Y;14)(p11;q32) IGH/CRLF2 194 Daniel Martinez-Anaya, Rocio Juárez-Velázquez, Dafné Moreno-Lorenzana, Patricia Pérez-Vera Case Report Section Isolated 1q21 rearrangement der(20)t(1;20)(q21;p13) with telomere involvement of 20p in a case of longstanding myelodysplastic syndrome 200 Lubomir Mitev, Liliya Grahlyova, Aselina Asenova, Verginia Uzunova, Julian Raynov A new case of adult Acute Myeloid Leukemia with t(3;3)(p24;q26) 204 Bo Yuan,
Load more

Recommended publications
  • Mirnas Generated from Meg3-Mirg Locus Are Downregulated During Aging
    www.aging-us.com AGING 2021, Vol. 13, No. 12 Research Paper miRNAs generated from Meg3-Mirg locus are downregulated during aging Ana-Mihaela Lupan1,*, Evelyn-Gabriela Rusu1,*, Mihai Bogdan Preda1, Catalina Iolanda Marinescu1, Cristina Ivan2, Alexandrina Burlacu1 1Laboratory of Stem Cell Biology, Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Bucharest 050568, Romania 2Department of Experimental Therapeutics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA *Equal contribution Correspondence to: Alexandrina Burlacu; email: [email protected] Keywords: aging, miRNA, Meg3-Mirg locus, cardiac fibroblasts, heart ventricles Received: October 31, 2020 Accepted: June 2, 2021 Published: June 22, 2021 Copyright: © 2021 Lupan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Aging determines a multilevel functional decline and increases the risk for cardiovascular pathologies. MicroRNAs are recognized as fine tuners of all cellular functions, being involved in various cardiac diseases. The heart is one of the most affected organs in aged individuals, however little is known about the extent and robustness to which miRNA profiles are modulated in cardiac cells during aging. This paper provides a comprehensive characterization of the aging-associated miRNA profile in the murine cardiac fibroblasts, which are increasingly recognized for their active involvement in the cardiac physiology and pathology. Next- generation sequencing of cardiac fibroblasts isolated from young and old mice revealed that an important fraction of the miRNAs generated by the Meg3-Mirg locus was downregulated during aging.
    [Show full text]
  • Insights Into Transcription Through Nascent RNA Sequencing
    Insights into transcription through nascent RNA sequencing by Artur Botelho Veloso A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Bioinformatics) in The University of Michigan 2014 Doctoral Committee: Professor Mats E.D. Ljungman, Chair Associate Professor Scott E. Barolo Professor Daniel M. Burns Jr. Assistant Professor Hui Jiang Professor Kerby A. Shedden Associate Professor Thomas E. Wilson c Artur B Veloso 2014 All Rights Reserved Para os meus pais, L´eae Rog´erio. ii ACKNOWLEDGEMENTS At´eonde eu me lembro, o meu interesse em ci^enciae pesquisa me acompanhou durante toda a minha vida. Quando crian¸caeu me sentia fascinado pelo mundo cient´ıficoe almejava o dia em que eu faria parte desse mundo. Durante a ´ultima d´ecadaeu tive a oportunidade de perseguir esse sonho, mas isso foi feita a duras penas. A minha decis~aode mudar de pa´ıse deixar fam´ıliae amigos para tr´asn~ao foi tomada facilmente. Eu n~aoa teria tomado, no entanto, se n~aotivesse recebido tanto apoio dessas mesmas pessoas. Esse processo n~aofoi f´acilpara mim, assim como n~aofoi f´acilpara eles. Por isso, eu primeiramente gostaria de agradecer `as pessoas que tem me apoiado durante toda minha vida. Minha m~aee meu pai, L´eae Rog´erio,foram fundamentais em meu desenvolvimento. Al´emdas qualidades b´asicas que bons pais ensinam a filhos, eles me ajudaram a desenvolver um forte sentido de independ^encia.Essa independ^enciafoi fundamental na minha decis~aode estudar em outro pa´ıs. Outro aspecto importante nessa decis~aofoi a minha ambi¸c~ao.Uma das pessoas que tiveram o maior impacto nessa caracter´ıstica foi meu irm~ao,Cristiano.
    [Show full text]
  • Identification of Forensically Relevant Fluids and Tissues by Small RNA Profiling Author(S): Jack Ballantyne, Ph.D
    The author(s) shown below used Federal funding provided by the U.S. Department of Justice to prepare the following resource: Document Title: Identification of Forensically Relevant Fluids and Tissues by Small RNA Profiling Author(s): Jack Ballantyne, Ph.D. Document Number: 251895 Date Received: July 2018 Award Number: 2009-DN-BX-K255 This resource has not been published by the U.S. Department of Justice. This resource is being made publically available through the Office of Justice Programs’ National Criminal Justice Reference Service. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. National Center for Forensic Science University of Central Florida P.O. Box 162367 · Orlando, FL 32826 Phone: 407.823.4041 Fax: 407.823.4042 Web site: http://www.ncfs.org/ Biological Evidence _________________________________________________________________________________________________________ Identification of Forensically Relevant Fluids and Tissues by Small RNA Profiling FINAL REPORT December 16, 2013 Department of Justice, National Institute of justice Award Number: 2009-DN-BX-K255 (1 November 2009 – 31 December 2013) _________________________________________________________________________________________________________ Principal Investigator: Jack Ballantyne, PhD Professor Department of Chemistry Associate Director for Research National Center for Forensic Science P.O. Box 162367 Orlando, FL 32816-2366 Phone: (407) 823 4440 Fax: (407) 823 4042 e-mail: [email protected] 1 This resource was prepared by the author(s) using Federal funds provided by the U.S. Department of Justice. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.
    [Show full text]
  • Rejuvenation of Aged Heart Explant-Derived Cells for Repair of Ischemic Cardiomyopathy
    Rejuvenation of Aged Heart Explant-Derived Cells for Repair of Ischemic Cardiomyopathy Ghazaleh Rafatian This thesis is submitted to the Faculty of Graduate and Postdoctoral Studies as partial fulfillment of the Doctor of Philosophy program in Cellular Molecular Medicine. Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa, Ottawa, ON Supervisors: Darryl R Davis, MD Erik J Suuronen, PhD © Ghazaleh Rafatian, Ottawa, Canada, 2019 Table of Contents Sources of Funding................................................................................................................. VIII Abstract ..................................................................................................................................... IX List of Tables .............................................................................................................................. X List of Figures ........................................................................................................................... XI List of abbreviations ............................................................................................................... XIII Acknowledgments ................................................................................................................. XVII 1. INTRODUCTION ................................................................................................................... 1 1.1.1 Aging .............................................................................................................................
    [Show full text]
  • Mirna Expression Changes in Arsenic-Induced Skin Cancer in Vitro and in Vivo
    University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 8-2017 MiRNA expression changes in arsenic-induced skin cancer in vitro and in vivo. Laila Al-Eryani University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Medicine and Health Sciences Commons Recommended Citation Al-Eryani, Laila, "MiRNA expression changes in arsenic-induced skin cancer in vitro and in vivo." (2017). Electronic Theses and Dissertations. Paper 2767. https://doi.org/10.18297/etd/2767 This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. MIRNA EXPRESSION CHANGES IN ARSENIC-INDUCED SKIN CANCER IN VITRO AND IN VIVO By Laila Al-Eryani A Dissertation Submitted To The Faculty of the School Of Medicine of the University Of Louisville In Partial Fulfillment of the Requirements For The Degree Of Doctor of Philosophy in Pharmacology and Toxicology Department Of Pharmacology and Toxicology University Of Louisville Louisville, Kentucky August 2017 MIRNA EXPRESSION CHANGES IN ARSENIC-INDUCED SKIN CANCER IN VITRO AND IN VIVO By Laila Al-Eryani Dissertation approved on August 03, 2017 By the following Dissertation Committee: J. Christopher States, Ph.D. Carolyn M. Klinge Ph.D. Shesh N. Rai, Ph.D.
    [Show full text]
  • Human Cytomegalovirus Reprograms the Expression of Host Micro-Rnas Whose Target Networks Are Required for Viral Replication: a Dissertation
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2013-08-26 Human Cytomegalovirus Reprograms the Expression of Host Micro-RNAs whose Target Networks are Required for Viral Replication: A Dissertation Alexander N. Lagadinos University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Immunology and Infectious Disease Commons, Molecular Genetics Commons, and the Virology Commons Repository Citation Lagadinos AN. (2013). Human Cytomegalovirus Reprograms the Expression of Host Micro-RNAs whose Target Networks are Required for Viral Replication: A Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/M2R88R. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/683 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. HUMAN CYTOMEGALOVIRUS REPROGRAMS THE EXPRESSION OF HOST MICRO-RNAS WHOSE TARGET NETWORKS ARE REQUIRED FOR VIRAL REPLICATION A Dissertation Presented By Alexander Nicholas Lagadinos Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester In partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY August 26th, 2013 Program in Immunology and Virology
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • A Simple Array Platform for Microrna Analysis and Its Application in Mouse Tissues
    Downloaded from rnajournal.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press METHOD AsimplearrayplatformformicroRNAanalysis and its application in mouse tissues XIAOQING TANG,1 JOZSEF GAL,2 XUN ZHUANG,1 WANGXIA WANG,1 HAINING ZHU,2 and GUILIANG TANG1 1Gene Suppression Laboratory, Department of Plant and Soil Sciences and Kentucky Tobacco Research and Development Center, University of Kentucky, Lexington, Kentucky 40546-0236, USA 2Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, Kentucky 40536-0509, USA ABSTRACT MicroRNAs (miRNAs) are a novel class of small noncoding RNAs that regulate gene expression at the post-transcriptional level and play a critical role in many important biological processes. Most miRNAs are conserved between humans and mice, which makes it possible to analyze their expressions with a set of selected array probes. Here, we report a simple array platform that can detect 553 nonredundant miRNAs encompassing the entire set of miRNAs for humans and mice. The platform features carefully selected and designed probes with optimized hybridization parameters. Potential cross-reaction between mature miRNAs and their precursors was investigated. The array platform was used to analyze miRNAs in the mouse central nervous system (CNS, spinal cord and brain), and two other non-CNS organs (liver and heart). Two types of miRNAs, differentially expressed organ/tissue-associated miRNAs and ubiquitously expressed miRNAs, were detected in the array analysis. In addition to the previously reported neuron-related miR-124a, liver-related miR-122a, and muscle-related miR-133a, we also detected new tissue-associated miRNAs (e.g., liver-associated miR-194).
    [Show full text]
  • Co-Deregulated Mirna Signatures in Childhood Central Nervous System Tumors: in Search for Common Tumor Mirna-Related Mechanics
    cancers Article Co-Deregulated miRNA Signatures in Childhood Central Nervous System Tumors: In Search for Common Tumor miRNA-Related Mechanics George I. Lambrou 1 , Apostolos Zaravinos 2,3,* and Maria Braoudaki 4,* 1 Choremeio Research Laboratory, First Department of Pediatrics, National and Kapodistrian University of Athens, Thivon & Levadeias 8, Goudi, 11527 Athens, Greece; [email protected] 2 Department of Life Sciences, European University Cyprus, Diogenis Str., 6, Nicosia 2404, Cyprus 3 Cancer Genetics, Genomics and Systems Biology Group, Basic and Translational Cancer Research Center (BTCRC), Nicosia 1516, Cyprus 4 Department of Clinical, Pharmaceutical and Biological Science, School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, Hertfordshire, UK * Correspondence: [email protected] (A.Z.); [email protected] (M.B.); Tel.: +974-4403-7819 (A.Z.); +44-(0)-1707286503 (ext. 3503) (M.B.) Simple Summary: Childhood tumors of the central nervous system (CNS) constitute a grave disease and their diagnosis is difficult to be handled. To gain better knowledge of the tumor’s biology, it is essential to understand the underlying mechanisms of the disease. MicroRNAs (miRNAs) are small noncoding RNAs that are dysregulated in many types of CNS tumors and regulate their occurrence and development through specific signal pathways. However, different types of CNS tumors’ area are characterized by different deregulated miRNAs. Here, we hypothesized that CNS tumors could Citation: Lambrou, G.I.; Zaravinos, have commonly deregulated miRNAs, i.e., miRNAs that are simultaneously either upregulated or A.; Braoudaki, M. Co-Deregulated downregulated in all tumor types compared to the normal brain tissue, irrespectively of the tumor miRNA Signatures in Childhood sub-type and/or diagnosis.
    [Show full text]
  • An Abstract of the Thesis Of
    AN ABSTRACT OF THE THESIS OF Jimmy Bell for the degree of Master of Science in Computer Science presented on March 9, 2020. Title: Machine Learning Methods for the Discovery and Analysis of MicroRNAs. Abstract approved: ______________________________________________________ David A. Hendrix MicroRNAs are a highly conserved class of small endogenous RNA, about ~22nt in length, involved in post-transcriptional gene silencing and have prominent roles in disease and development. Though the process of microRNA discovery was once an arduous task, the advent of high throughput sequencing technology has resulted in novel microRNAs being discovered at a rapid rate. Several data-driven pipelines and machine learning-based methods have been devised so that the beginning stages of microRNA discovery can be performed in silico. Despite these efforts, several challenges have persisted in the computational prediction of microRNAs. These challenges include the identification of microRNAs with low expression, proper determination of the precursor span, and the precise labeling of the cleavage sites involved in their biogenesis. This thesis addresses these challenges with two new machine learning-based approaches. MiRWoods improves precursor detection and uses stacked random forests for the sensitive detection of microRNAs. We report that miRWoods has a 10% higher recall of annotated microRNAs when compared with other software. We applied this method to the genomes of human, mouse, Felis catus (cat) and Bos Taurus (cow) and identified hundreds of novel microRNAs in small RNA sequencing datasets. Our novel predictions include a microRNA in an intron of tyrosine kinase 2 (TYK2), that is present in both cat and cow, as well as a family of mirtrons with two instances in the human genome.
    [Show full text]
  • Micrornas As Epigenetic Modulators of FOLFOX Chemotherapy Response Trough Epithelial-Mesenchymal Transition in Colorectal Cancer
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 November 2020 Review. MicroRNAs as epigenetic modulators of FOLFOX chemotherapy response trough epithelial-mesenchymal transition in colorectal cancer Paula I. Escalante1,2, Luis A. Quiñones1,3* and Héctor R. Contreras2* 1 Laboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology (DOBC), Faculty of Medicine, University of Chile, Santiago, Chile. 2 Laboratory of Cellular and Molecular Oncology (LOCYM), Department of Basic and Clinical Oncology (DOBC), Faculty of Medicine, University of Chile, Santiago, Chile. 3 Latin American Network for the Implementation and Validation of Pharmacogenomic Clinical Guidelines (RELIVAF-CYTED), Madrid, Spain. * Correspondence: [email protected]; Tel.: +56-2-29786862/ +56-2-29786861 (H.C) and/or [email protected]; Tel.: +56-2-29770741 / +56-2-29770743 (L.Q). Abstract: The FOLFOX scheme, based on the association of 5-fluorouracil and oxaliplatin, is the most frequently indicated chemotherapy scheme for patients diagnosed with metastatic colorectal cancer. Nevertheless, development of chemoresistance is one of the major challenges associated with this disease. It has been reported that epithelial-mesenchymal transition (EMT) is implicated in microRNA-driven modulation of tumor cells response to 5-fluorouracil and oxaliplatin. Besides, from pharmacogenomic research it is known that overexpression of genes encoding dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), methylenetetrahydrofolate reductase (MTHFR), the DNA repair enzymes ERCC1, ERCC2, and XRCC1, and the phase 2 enzyme GSTP1 impair the response to FOLFOX. It has been observed that EMT is associated with overexpression of DPYD, TYMS, ERCC1, and GSTP1. In this review we investigated the role of miRNAs as EMT promotors in tumor cells, and its potential effect on upregulation of DPYD, TYMS, MTHFR, ERCC1, ERCC2, XRCC1 and GSTP1 expression, which would lead to resistance of CRC tumor cells to 5-fluorouracil and oxaliplatin.
    [Show full text]
  • Cardamonin Inhibits Colonic Neoplasia Through Modulation of Microrna Expression Received: 17 March 2017 Shirley James1, Jayasekharan S
    www.nature.com/scientificreports OPEN Cardamonin inhibits colonic neoplasia through modulation of MicroRNA expression Received: 17 March 2017 Shirley James1, Jayasekharan S. Aparna1, Aswathy Mary Paul2, Manendra Babu Accepted: 9 October 2017 Lankadasari1,3, Sabira Mohammed1,3, Valsalakumari S. Binu4, Thankayyan R. Published: xx xx xxxx Santhoshkumar1, Girijadevi Reshmi2 & Kuzhuvelil B. Harikumar 1 Colorectal cancer is currently the third leading cause of cancer related deaths. There is considerable interest in using dietary intervention strategies to prevent chronic diseases including cancer. Cardamonin is a spice derived nutraceutical and herein, for the first time we evaluated the therapeutic benefits of cardamonin in Azoxymethane (AOM) induced mouse model of colorectal cancer. Mice were divided into 4 groups of which three groups were given six weekly injections of AOM. One group served as untreated control and remaining groups were treated with either vehicle or Cardamonin starting from the same day or 16 weeks after the first AOM injection. Cardamonin treatment inhibited the tumor incidence, tumor multiplicity, Ki-67 and β-catenin positive cells. The activation of NF-kB signaling was also abrogated after cardamonin treatment. To elucidate the mechanism of action a global microRNA profiling of colon samples was performed. Computational analysis revealed that there is a differential expression of miRNAs between these groups. Subsequently, we extend our findings to human colorectal cancer and found that cardamonin inhibited the growth, induces cell cycle arrest and apoptosis in human colorectal cancer cell lines. Taken together, our study provides a better understanding of chemopreventive potential of cardamonin in colorectal cancer. Colorectal cancer (CRC) is the third most common cancer, and its frequency is increasing1.
    [Show full text]